About Align Technology, Inc. - Common Stock (ALGN)
Align Technology is a medical device company known primarily for its innovative dental products, including the Invisalign system, which offers a clear alternative to traditional metal braces for orthodontic treatment. The company focuses on transforming patients' smiles through advanced 3D computer modeling and digital scanning technologies, enabling customized treatment plans. In addition to its flagship product, Align Technology also produces a range of other tools and software that enhance dental practice efficiency and patient care, serving both orthodontists and general dentists. By combining cutting-edge technology with a commitment to improving oral health, Align Technology aims to empower patients and revolutionize the field of orthodontics. Read More
Dental technology company Align Technology (NASDAQ:ALGN) announced better-than-expected revenue in Q4 CY2025, with sales up 5.3% year on year to $1.05 billion. The company expects next quarter’s revenue to be around $1.02 billion, close to analysts’ estimates. Its non-GAAP profit of $3.29 per share was 10.8% above analysts’ consensus estimates.
Dental technology company Align Technology (NASDAQ:ALGN) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 5.3% year on year to $1.05 billion. The company expects next quarter’s revenue to be around $1.02 billion, close to analysts’ estimates. Its non-GAAP profit of $3.29 per share was 10.8% above analysts’ consensus estimates.
Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today reported financial results for the fourth quarter ("Q4'25") and year ended December 31, 2025 ("2025"). Q4'25 total revenues were $1,047.6 million, up 5.2% sequentially and up 5.3% year-over-year. Q4'25 total revenues were unfavorably impacted by foreign exchange of approximately $3.0 million or 0.3% sequentially and favorably impacted by approximately $14.8 million or 1.4% year-over-year.(1) Q4'25 Clear Aligner revenues were $838.1 million, up 4.0% sequentially and up 5.5% year-over-year. Q4'25 Clear Aligner revenues were unfavorably impacted by foreign exchange of approximately $2.3 million or 0.3% sequentially and favorably impacted by approximately $12.4 million or 1.5% year-over-year.(1) Q4'25 Clear Aligner volume of 676.9 thousand cases was up 4.5% sequentially and up 7.7% year-over-year. Q4'25 Imaging Systems and CAD/CAM Services revenues were $209.4 million, up 10.3% sequentially and up 4.2% year-over-year. Q4'25 Imaging Systems and CAD/CAM Services revenues were unfavorably impacted by foreign exchange of approximately $0.7 million or 0.3% sequentially and favorably impacted by approximately $2.5 million or 1.2% year-over-year.(1)
Align Technology, Inc. (NASDAQ: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced its collaboration with the University of Bern on Switzerland’s first Swiss Oral Health Study – an epidemiological initiative led by Professor Dr. Hendrik Meyer-Lückel, director of the Clinic for Conservative, Preventive, and Pediatric Dentistry at the University of Bern.
Wall Street has issued downbeat forecasts for the stocks in this article.
These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Even if a company is profitable, it doesn’t always mean it’s a great investment.
Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Over the last six months, Align Technology’s shares have sunk to $170.94, producing a disappointing 14.2% loss - a stark contrast to the S&P 500’s 11.3% gain. This might have investors contemplating their next move.
Align Technology, Inc. (NASDAQ: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced a new initiative with the Canadian Foundation for the Advancement of Orthodontics (CFAO). Under this initiative, Align has committed to support Invisalign treatment for 30 eligible patients through CFAO’s Smiles4Canada program, a public health goodwill program founded in 2016 to put a smile, both figuratively and literally, on a young person with significant orthodontic needs, whose family does not have the financial resources to pay for the procedure.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Align Technology, Inc. (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it will report fourth quarter and full year 2025 financial results on Wednesday, February 4, 2026, after the close of market. Financial results will be released at 4:00 p.m. ET (2:00 p.m. MT) and will be available on the Investor Relations section of the Align website at http://investor.aligntech.com.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Those leading the charge have realized strong financial performance,
and over the past six months, the industry’s 13.5% return has closely followed the S&P 500.
Align Technology, Inc. (NASDAQ: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software, today shared highlights from its participation at the Greater New York Dental Meeting (GNYDM) 2025, one of the largest annual dental congresses in the United States.
Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced top-tier recognition in the 2025 All-America Executive Team rankings published by Extel Insights (formerly Institutional Investor Research), which evaluates the quality of investor relations programs, leadership, and governance as voted on by the buy- and sell-side analyst community. Align earned multiple #1, #3, and top 10 positions for its executive leadership, board, investor relations program, and investor/analyst events, in the Health Care Technology & Distribution sector and Large-Cap ($10B–$50B) market segment. The company also earned the distinction of Most Honored Company in the 2025 All-America Executive Team survey which celebrates the U.S. Companies that ranked at the top of the survey.
Shares of dental technology company Align Technology (NASDAQ:ALGN)
jumped 6.2% in the afternoon session after the company announced the commercial availability of its Invisalign System with mandibular advancement in the Philippines. This new product was designed to correct specific jaw and teeth alignment issues in growing patients by simultaneously moving the lower jaw forward while straightening teeth, expanding the company's treatment portfolio. In other news, Align Technology also concluded an academic program roadshow across the Middle East to support digital orthodontic education. The stock's positive move came despite analysts at Evercore ISI lowering their price target on the shares to $170 from $220, though the firm did maintain its "Outperform" rating, suggesting investors focused more on the product news.
The landscape of dental care is undergoing an unprecedented transformation, moving beyond traditional methods into an era defined by precision, efficiency, and enhanced patient experience. At the heart of this revolution is digital dentistry, a broad spectrum of technological advancements that are fundamentally reshaping how oral health is diagnosed, treated, and managed. Leading this charge [...]